Publication
2025
- Evans, M. et al. 2025. Post-operative radiotherapy for oral cavity squamous cell carcinoma: Review of the data guiding the selection and the delineation of post-operative target volumes. Radiotherapy & Oncology 207 110880. (10.1016/j.radonc.2025.110880)
- Evans, M. et al. 2025. Delineation of the post-operative primary tumour and nodal clinical target volumes in oral cavity squamous cell carcinoma: European Society for Radiotherapy and Oncology (ESTRO) clinical guidelines.. Radiotherapy & Oncology 212 111135. (10.1016/j.radonc.2025.111135)
- Evans, M. et al. 2025. Correlation between imaging-detected and pathological extranodal extension in a randomised trial in Human Papillomavirus-positive oropharyngeal cancer. British Journal of Cancer (10.1038/s41416-025-03291-z)
- Ho, A. S. et al., 2025. Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis. The Lancet Oncology 26 (8), pp.1113-1122. (10.1016/S1470-2045(25)00281-5)
- Shaw, R. et al., 2025. RAPTOR: Randomised controlled trial of PENTOCLO (pentoxifylline-tocopherol-clodronate) in mandibular osteoradionecrosis—study protocol for an open-label phase II randomised controlled superiority trial. Trials 26 (1) 254. (10.1186/s13063-025-08966-9)
2024
- Fuentes, J. D. B. et al., 2024. High-grade neuroendocrine head and neck cancer: Case series and review of the literature. Current Problems in Cancer 51 101105. (10.1016/j.currproblcancer.2024.101105)
- O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
- Thomson, D. et al., 2024. Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD). International Journal of Radiation Oncology - Biology - Physics 119 , pp.771-782. (10.1016/j.ijrobp.2023.11.055)
2019
- Jadon, R. et al. 2019. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology 14 (1), pp.-. 57. (10.1186/s13014-019-1262-8)
2018
- Parkinson, C. et al. 2018. Target volume delineation of FDG PET images post one cycle of induction chemotherapy in oropharyngeal cancer using advanced automated segmentation methods. Presented at: ESTRO 37 Barcelona 20-24 April 2018.
- Pirotte, E. F. et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13 (12), pp.-. e0207934. (10.1371/journal.pone.0207934)
Articles
- Evans, M. et al. 2025. Post-operative radiotherapy for oral cavity squamous cell carcinoma: Review of the data guiding the selection and the delineation of post-operative target volumes. Radiotherapy & Oncology 207 110880. (10.1016/j.radonc.2025.110880)
- Evans, M. et al. 2025. Delineation of the post-operative primary tumour and nodal clinical target volumes in oral cavity squamous cell carcinoma: European Society for Radiotherapy and Oncology (ESTRO) clinical guidelines.. Radiotherapy & Oncology 212 111135. (10.1016/j.radonc.2025.111135)
- Evans, M. et al. 2025. Correlation between imaging-detected and pathological extranodal extension in a randomised trial in Human Papillomavirus-positive oropharyngeal cancer. British Journal of Cancer (10.1038/s41416-025-03291-z)
- Fuentes, J. D. B. et al., 2024. High-grade neuroendocrine head and neck cancer: Case series and review of the literature. Current Problems in Cancer 51 101105. (10.1016/j.currproblcancer.2024.101105)
- Ho, A. S. et al., 2025. Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis. The Lancet Oncology 26 (8), pp.1113-1122. (10.1016/S1470-2045(25)00281-5)
- Jadon, R. et al. 2019. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology 14 (1), pp.-. 57. (10.1186/s13014-019-1262-8)
- O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
- Pirotte, E. F. et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13 (12), pp.-. e0207934. (10.1371/journal.pone.0207934)
- Shaw, R. et al., 2025. RAPTOR: Randomised controlled trial of PENTOCLO (pentoxifylline-tocopherol-clodronate) in mandibular osteoradionecrosis—study protocol for an open-label phase II randomised controlled superiority trial. Trials 26 (1) 254. (10.1186/s13063-025-08966-9)
- Thomson, D. et al., 2024. Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD). International Journal of Radiation Oncology - Biology - Physics 119 , pp.771-782. (10.1016/j.ijrobp.2023.11.055)
Conferences
- Parkinson, C. et al. 2018. Target volume delineation of FDG PET images post one cycle of induction chemotherapy in oropharyngeal cancer using advanced automated segmentation methods. Presented at: ESTRO 37 Barcelona 20-24 April 2018.